The results of a retrospective study indicated that patients with metastatic gastrointestinal stromal tumors (GIST) who are able to achieve complete macroscopic surgical resection of their disease may be able to achieve long-term survival.
In recent years we have been able to gain valuable information from the data produced by tissue donations to the GIST Collaborative Tissue Bank.
A recent nonrandomized study has shown that imatinib rechallenge impacted the survival rate for patients with advanced or metastatic gastrointestinal stromal tumor (GIST).
The LRG helped fund research by the University of Pittsburgh Cancer Institute (UPCI) to screen a library of FDA-approved anticancer drugs that previously wouldn’t have been considered as a treatment for GIST. UPCI scientists have been surprised at [...]
There are two new treatments that may have an impact on fighting GIST – immunotherapy and MRI-guided radiation. The LRG is continually looking into new treatments for GIST.
In December, the Life Raft Group launched its “We Are the Cure” campaign to fund GIST research. I sat down with Norman to find out more about The LRG GIST research team and the campaign’s progress to date.
Accomplishments—Recent Progress: 1. Using mouse models, successfully attacked GIST with antibodies, essentially telling immune system to eat the cancer cells.
The Life Raft Group is pleased to formally announce the creation of its first ever Global Medical Team. This team, which consists of leading physicians throughout the world, will provide the LRG the opportunity to [...]
From October 30th to November 2nd the Life Raft Group staff members attended the annual Connective Tissue Oncology Society (CTOS) Meeting in NYC.
The AACR has released it's 2013 Cancer Progress report. The report is a comprehensive educational tool that illustrates the return on investments in cancer research and biomedical science. It discusses the various ways medical teams continue [...]
